Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Hits 52-Week High

NEW YORK (GenomeWeb News) – After matching a 52-week high of $23 on Monday before pulling back to close at $22.33 on the Nasdaq, up 6.4 percent for the day, shares of Sequenom hit a new 52-week high on Tuesday morning of $24.50.
 
The San Diego-based firm’s stock bucked the trend on a dismal Monday for the stock market, which saw the Dow Jones Industrial Average lose 241.81, or 2.1 percent, while the Nasdaq dropped 2 percent. The $23 per share price matched the firm’s 52-week high reached on July 16.
 
Sequenom’s shares have risen sharply since the firm announced in early June positive results from a clinical study of its Down syndrome test, with no false positives reported in the study. It expects to release the results of a second, larger study of the test later this year.
 
Some analysts have speculated that the market for such a test is potentially worth more than $2 billion.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.